Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

Introducing Therioepistemology: the study of how knowledge is gained from animal research

(2017) Joseph P Garner et al.   LAB ANIMAL

Age exacerbates abnormal protein expression in a mouse model of Down syndrome

(2017) Md. Mahiuddin Ahmed et al.   NEUROBIOLOGY OF AGING

Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome

(2017) Alexander M. Kleschevnikov et al.   NEUROBIOLOGY OF DISEASE

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

(2017) Megan Stringer et al.   PHYSIOLOGY & BEHAVIOR

Specific age-related molecular alterations in the cerebellum of Down syndrome mouse models

(2016) Nicole Créau et al.   BRAIN RESEARCH

Mouse-based genetic modeling and analysis of Down syndrome

(2016) Zhuo Xing et al.   BRITISH MEDICAL BULLETIN

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

(2016) Hyeongki Kim et al.   Disease Models & Mechanisms

Mouse models of Down syndrome: gene content and consequences

(2016) Meenal Gupta et al.   MAMMALIAN GENOME

Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model

(2016) Irushi Abeysekera et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Down syndrome and the complexity of genome dosage imbalance

(2016) Stylianos E. Antonarakis   NATURE REVIEWS GENETICS

Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome

(2016) Fiorenza Stagni et al.   NEUROSCIENCE

Selective inhibition of the kinase DYRK1A by targeting its folding process

(2016) Isao Kii et al.   Nature Communications

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

(2016) Arnaud Duchon et al.   Frontiers in Behavioral Neuroscience

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice

(2015) Gaëlle Naert et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Genetic dissection of the Down syndrome critical region

(2015) Xiaoling Jiang et al.   HUMAN MOLECULAR GENETICS

Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomicDyrk1a

(2015) Joshua D. Blazek et al.   HUMAN MOLECULAR GENETICS

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model

(2015) Megan Stringer et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models

(2015) Benoit Souchet et al.   Frontiers in Behavioral Neuroscience

Timing of therapies for Down syndrome: the sooner, the better

(2015) Fiorenza Stagni et al.   Frontiers in Behavioral Neuroscience

Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome

(2015) Silvina Catuara-Solarz et al.   Frontiers in Behavioral Neuroscience

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome

(2015) Sònia Najas et al.   EBioMedicine

DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

(2014) Walter Becker et al.   CNS & Neurological Disorders-Drug Targets

Prenatal treatment of Down syndrome

(2014) Fayçal Guedj et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Prefrontal Deficits in a Murine Model Overexpressing the Down Syndrome Candidate Gene Dyrk1a

(2014) A. Thomazeau et al.   JOURNAL OF NEUROSCIENCE

Domains of genome-wide gene expression dysregulation in Down’s syndrome

(2014) Audrey Letourneau et al.   NATURE

Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage

(2014) Benoit Souchet et al.   NEUROBIOLOGY OF DISEASE

Overexpression of Dyrk1A Is Implicated in Several Cognitive, Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down Syndrome

(2014) Susana García-Cerro et al.   PLoS One

Fabrication of coated bovine serum albumin (BSA)–epigallocatechin gallate (EGCG) nanoparticles and their transport across monolayers of human intestinal epithelial Caco-2 cells

(2014) Zheng Li et al.   Food & Function

New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome

(2014) Joongkyu Park et al.   Experimental Neurobiology

Commonality in Down and fetal alcohol syndromes

(2013) Jeffrey P. Solzak et al.   BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY

A patient with partial trisomy 21 and 7q deletion expresses mild Down syndrome phenotype

(2013) I. Papoulidis et al.   GENE

Protonation of Epigallocatechin-3-gallate (EGCG) Results in Massive Aggregation and Reduced Oral Bioavailability of EGCG-Dispersed Selenium Nanoparticles

(2013) Shanshan Wu et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans

(2013) Rafael De la Torre et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A

(2013) Meritxell Pons-Espinal et al.   NEUROBIOLOGY OF DISEASE

Dyrk1A Is Dynamically Expressed on Subsets of Motor Neurons and in the Neuromuscular Junction: Possible Role in Down Syndrome

(2013) Gloria Arque et al.   PLoS One

Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn

(2012) Elizabeth Kida et al.   EXPERIMENTAL NEUROLOGY

A patient with Down syndrome with a de novo derivative chromosome 21

(2012) Zafer Cetin et al.   GENE

Loss of Correlations among Proteins in Brains of the Ts65Dn Mouse Model of Down Syndrome

(2012) Md. Mahiuddin Ahmed et al.   JOURNAL OF PROTEOME RESEARCH

DYRK1A: A master regulatory protein controlling brain growth

(2012) Fayçal Guedj et al.   NEUROBIOLOGY OF DISEASE

Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome

(2012) Xavier Altafaj et al.   NEUROBIOLOGY OF DISEASE

Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities

(2012) Noemí Rueda et al.   NEURAL PLASTICITY

Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes

(2011) Mireia Vilardell et al.   BMC GENOMICS

The use of mouse models to understand and improve cognitive deficits in Down syndrome

(2011) I. Das et al.   Disease Models & Mechanisms

Green tea polyphenols in drug discovery: a success or failure?

(2011) Thomas J Smith   Expert Opinion on Drug Discovery

Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)

(2010) Tatyana Adayev et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Updated national birth prevalence estimates for selected birth defects in the United States, 2004-2006

(2010) Samantha E. Parker et al.   BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY

The role of DYRK1A in neurodegenerative diseases

(2010) Jerzy Wegiel et al.   FEBS Journal

Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome

(2010) Lina Chakrabarti et al.   NATURE NEUROSCIENCE

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

(2010) Yasushi Ogawa et al.   Nature Communications

Complex contributions ofEts2to craniofacial and thymus phenotypes of trisomic “Down syndrome” mice

(2009) Cheryl A. Hill et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model

(2009) Jennifer H. K. Choi et al.   JOURNAL OF NEUROCHEMISTRY

Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A

(2009) Fayçal Guedj et al.   PLoS One

DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase

(2009) Christophe Noll et al.   PLoS One

The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies

(2009) J. O. Korbel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome

(2008) Jon Ortiz-Abalia et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Genotype–phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21

(2008) Robert Lyle et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development

(2008) Barbara Hämmerle et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome

(2008) Fei Liu et al.   FASEB JOURNAL

Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801

(2008) A. Siddiqui et al.   GENES BRAIN AND BEHAVIOR

Gene expression variation increase in trisomy 21 tissues

(2008) Ching Yu Chou et al.   MAMMALIAN GENOME